Genomic Cancer Panel and Profiling Market Report: 2027-2031 Forecast, Technology and Partnering Opportunities by Cancer Type, Clinical Use, Panel Size, Sample, Customer and Country - Strategic Analysis of 97 Companies

1.1 Situation Analysis
1.2 Market Snapshot
1.3 Key Findings
1.4 Investment & Strategic Thesis

2.1 Market Definition
2.2 Segments
2.3 Forecast Approach
2.4 Data Sources
2.5 Limitations
2.6 Authors

3.1 What are Genomic Cancer Panels and Profiling?
3.2 The Genomics of Cancer
3.3 Panel Sizes
3.4 DNA, RNA and Methylation
3.5 Tissue, Blood and Other Fluids
3.6 Clinical Uses and the Patient Journey
3.7 Platforms and Methods
3.8 Industry Structure and Players
3.9 Perspective: Healthcare Spending
3.10 Laboratory Structure: Central versus Local Testing
3.11 Pricing: Comprehensive Profiling vs Exome and Genome Sequencing
3.12 Potential Market Opportunity: Screening, Diagnosis and Therapy Selection

4.1 Global Market Overview by Country
4.2 Global Market by Cancer Type - Overview
4.3 Global Market by Clinical Use - Overview
4.4 Global Market by Panel Size - Overview
4.5 Global Market by Sample - Overview
4.6 Global Market by Customer - Overview

5.1 Routes to Market
5.2 FDA-Approved and Cleared Tissue Panels
5.3 FDA-Approved Blood Panels
5.4 Distributable Kits and Central-Laboratory Tests
5.5 Major Laboratory-Developed Panels
5.6 Haematology Panels
5.7 Hereditary Cancer Panels
5.8 MRD and Screening Panels
5.9 Japan and Europe
5.10 Key Approvals, 2024-2026

6.1 How Evidence Drives Adoption
6.2 Therapy Selection and Comprehensive Profiling
6.3 Whole Exome and Whole Genome in Clinical Use
6.4 Hereditary Risk and Germline Evidence
6.5 Diagnosis and Prognosis
6.6 MRD and Monitoring
6.7 Screening and Early Detection
6.8 Evidence Gaps and Their Market Effects
6.9 Test Pipeline, 2027-2031

7.1 Overview
7.2 Target Enrichment: Hybrid Capture and Amplicon
7.3 DNA Plus RNA
7.4 Complex Biomarkers and Signatures
7.5 Clinical Whole Exome and Whole Genome
7.6 Sequencing Platforms
7.7 Instrumentation, Automation and Bioinformatics
7.8 Instrumentation and Automation
7.9 Tissue and Blood Workflows
7.10 Emerging Technologies

8.1 Pharma as a Customer
8.2 Business Models
8.3 Selected Partnerships
8.4 Pricing and Reimbursement as Part of the Model
8.5 Consolidation
8.6 Economics and Risks

9.1 Overview: A Two-Track Market
9.2 United States: FDA
9.3 United States: Reimbursement
9.4 Europe
9.5 Japan
9.6 China
9.7 Other Markets
9.8 Implications for the Forecast

10.1 Intellectual Property
10.2 Litigation
10.3 Pricing

11.1 Overview
11.2 Demand: Cancer Burden and Targeted Therapy
11.3 Company Landscape
11.4 NMPA-Approved NGS Panels
11.5 Pricing, Procurement and Reimbursement
11.6 From Central Laboratories to Hospital Kits
11.7 Illumina, Export Restrictions and Domestic Sequencers
11.8 Capital Markets and Consolidation
11.9 Outlook and Implications for Global Companies

12.1 Deal Database
12.2 Deal Themes
12.3 Valuation Trends
12.4 Outlook for Deal-Making

13.1 Recent Developments - Importance and How to Use This Section
13.2 Medicare Sets Payment for Illumina TruSight Oncology Comprehensive
13.3 Illumina and Labcorp Expand Precision Oncology Collaboration
13.4 FDA Approves Next-Generation Guardant360 Liquid CDx
13.5 FDA Clears Datar Cancer Genetics' CellDx-Tissue DNA and RNA Profiling Assay
13.6 Tempus to Acquire Personalis
13.7 Caris Reports Record Second Quarter and Raises 2026 Guidance
13.8 NCCN Recommends Germline Panel Testing for All Colorectal, Endometrial and Gastric Cancer Patients
13.9 Ambry Genetics Reaches One Millionth Combined RNA and DNA Hereditary Test
13.10 Roche Launches Axelios 1 Sequencer Based on SBX Technology
13.11 FDA Rescinds Its Laboratory-Developed Test Rule

14.1 Where Panel Testing Is Done
14.2 Distributed In-House Testing
14.3 Turnaround Time
14.4 Tissue Stewardship and Test Failure
14.5 The Sample-to-Report Workflow
14.6 Sequencer and Reagent Supply
14.7 Automation
14.8 Staffing
14.9 Bioinformatics Pipelines and Interpretation
14.10 Quality, Accreditation and Proficiency
14.11 Implications for Suppliers

15.1 Market Structure
15.2 Industry Structure: Players in a Dynamic Market
15.3 Central Laboratories versus Distributed Testing
15.4 Leading Companies by Segment
15.5 Competitive Positioning
15.6 Estimated Competitive Tiers
15.7 Leading Companies
15.8 Sequencer Competition
15.9 China Players
15.10 Emerging Players
15.11 Outlook

16.1 Factors Driving Growth
16.2 Factors Limiting Growth
16.3 SWOT Analysis
16.4 Porter's Five Forces
16.5 Key Investment Risks
16.6 Investment Risk Matrix

17.1 Guidance for Executives, Marketing, Sales and Business Development
17.2 White-Space Opportunities
17.3 Partnering Strategy Guidance
17.4 Recommendations by Company Type
17.5 Guide for Management Consultants and Investment Advisors

18.1 Lung
18.2 Breast
18.3 Colorectal
18.4 Prostate
18.5 Gynecological
18.6 Blood Cancers
18.7 Other Cancers

19.1 Therapy Selection & CDx
19.2 Hereditary Risk & Germline
19.3 Diagnosis & Prognosis
19.4 MRD & Monitoring
19.5 Screening & Early Detection

20.1 Comprehensive Genomic Profiling
20.2 Targeted Panels
20.3 Hotspot Panels

21.1 Tissue
21.2 Blood (Liquid Biopsy)
21.3 Other Fluids

22.1 Clinical Laboratories
22.2 Pharma & CRO
22.3 Research

23.1 4baseCare
23.2 Abbott (Exact Sciences)
23.3 ACT Genomics (Delta Electronics)
23.4 Agendia
23.5 Agilent Technologies
23.6 Almac Diagnostic Services
23.7 Ambry Genetics (Tempus)
23.8 Amoy Diagnostics (AmoyDx)
23.9 ARUP Laboratories
23.10 Asuragen (Bio-Techne)
23.11 Berry Oncology
23.12 BGI Genomics
23.13 BillionToOne
23.14 Biocartis
23.15 Biodesix
23.16 Biofidelity
23.17 Bio-Rad Laboratories
23.18 Bio-Techne
23.19 BostonGene
23.20 Burning Rock Biotech
23.21 Caris Life Sciences
23.22 Castle Biosciences
23.23 Celemics
23.24 Datar Cancer Genetics
23.25 Diaceutics
23.26 Element Biosciences
23.27 Eurofins Scientific
23.28 Foundation Medicine (Roche)
23.29 Freenome
23.30 Fulgent Genetics
23.31 Genecast Biotechnology
23.32 GeneDx
23.33 Geneplus-Beijing
23.34 Geneseeq Technology
23.35 Gene Solutions
23.36 Genetron Health
23.37 Genomic Testing Cooperative
23.38 GenomOncology
23.39 GRAIL
23.40 Guardant Health
23.41 H.U. Group
23.42 Illumina
23.43 Inocras
23.44 Integrated DNA Technologies (Danaher)
23.45 Interpace Biosciences
23.46 Invivoscribe
23.47 Labcorp
23.48 Lucence
23.49 Macrogen
23.50 Mayo Clinic Laboratories
23.51 MDxHealth
23.52 MedGenome
23.53 MGI Tech
23.54 Mirxes
23.55 Myriad Genetics
23.56 Natera
23.57 NeoGenomics
23.58 NGeneBio
23.59 Nonacus
23.60 Novogene
23.61 Oncocyte
23.62 OncoDNA
23.63 Oncompass Medicine
23.64 OneCell Diagnostics
23.65 OrigiMed
23.66 Oxford Nanopore Technologies
23.67 Pacific Biosciences
23.68 Paragon Genomics
23.69 Personalis (Tempus AI)
23.70 Pillar Biosciences
23.71 Precede Biosciences
23.72 Precipio
23.73 Predicine
23.74 Promega
23.75 Q2 Solutions (IQVIA)
23.76 Qiagen
23.77 Quest Diagnostics
23.78 Revvity
23.79 Roche Diagnostics
23.80 SeqOne
23.81 Singlera Genomics
23.82 Sonic Healthcare
23.83 SOPHiA GENETICS
23.84 Strand Life Sciences
23.85 Strata Oncology
23.86 Synlab
23.87 Sysmex (Sysmex Inostics)
23.88 Takara Bio
23.89 Tempus AI
23.90 Thermo Fisher Scientific
23.91 Twist Bioscience
23.92 Ultima Genomics
23.93 Unilabs
23.94 Vela Diagnostics
23.95 Velsera
23.96 Veracyte
23.97 Watchmaker Genomics

24.1 Abbreviations
24.2 Developments Archive
24.3 Report Limitations Restated

Table 1 Genomic Cancer Panel and Profiling Market Summary, 2026 and 2031
Table 2 Leading Genomic Cancer Panels and Profiling Services
Table 3 How CANPANEL and CANMDx Define Their Markets
Table 4 Forecast Segments
Table 5 Panel Sizes and Their Uses
Table 6 The Cancer Patient Journey and Panel Testing
Table 7 Main Types of Player in Genomic Cancer Panels
Table 8 Selected U.S. Medicare Prices for Profiling Tests
Table 9 Potential Screening Market: Lung, Breast & Colorectal
Table 10 Potential Screening Market: Prostate, Other & All
Table 11 Potential Cancer Diagnosis Market Size
Table 12 Potential Therapy Selection Market Size
Table 13 Global Market by Country
Table 14 Global Market by Cancer Type
Table 15 Global Market by Clinical Use
Table 16 Global Market by Panel Size
Table 17 Global Market by Sample
Table 18 Global Market by Customer
Table 19 Selected FDA-Approved and Cleared Tissue Panels and CGP Tests, October 2026
Table 20 FDA-Approved and Authorised Liquid Biopsy Panels, October 2026
Table 21 Central-Laboratory and Distributed Panel Models Compared
Table 22 Major Central-Laboratory and LDT Panel Menus, October 2026
Table 23 Selected Hereditary Cancer Panels
Table 24 Main CGP Tests Approved in Japan
Table 25 Selected Panel Approvals and Decisions, 2024-2026
Table 26 Evidence Status by Clinical Use
Table 27 Tumour-Agnostic Approvals Relevant to Panel Testing
Table 28 Selected Genomic Panel Pipeline Items, 2027-2031
Table 29 The Panel Size Spectrum
Table 30 Amplicon and Hybrid Capture Enrichment Compared
Table 31 Sequencing Platforms Used in Genomic Cancer Testing, October 2026
Table 32 Business Models in Genomic Cancer Panels
Table 33 Selected Genomic Panel Partnerships
Table 34 Regulatory Routes for Genomic Cancer Panels in the U.S.
Table 35 Selected Litigation Affecting Genomic Cancer Panels
Table 36 Indicative U.S. Prices for Genomic Cancer Panels
Table 37 Selected Companies in China's Genomic Profiling Market
Table 38 Selected NMPA-Approved and Pending Panels
Table 39 Selected Deals in Genomic Cancer Panels and Profiling, 2023-2026
Table 40 Central and Distributed Panel Testing Compared
Table 41 Sample-to-Report Workflow for a Genomic Cancer Panel
Table 42 Leading Companies by Segment
Table 43 Competitive Positioning of Leading Panel Companies
Table 44 Estimated Competitive Tiers in Genomic Cancer Panels
Table 45 Sequencer Competition in Cancer Panel Testing
Table 46 Factors Driving Growth
Table 47 Factors Limiting Growth
Table 48 Investment Risk Matrix
Table 49 Recommendations by Company Type
Table 50 Lung by Country
Table 51 Breast by Country
Table 52 Colorectal by Country
Table 53 Prostate by Country
Table 54 Gynecological by Country
Table 55 Blood Cancers by Country
Table 56 Other Cancers by Country
Table 57 Therapy Selection & CDx by Country
Table 58 Hereditary Risk & Germline by Country
Table 59 Diagnosis & Prognosis by Country
Table 60 MRD & Monitoring by Country
Table 61 Screening & Early Detection by Country
Table 62 Comprehensive Genomic Profiling by Country
Table 63 Targeted Panels by Country
Table 64 Hotspot Panels by Country
Table 65 Tissue by Country
Table 66 Blood (Liquid Biopsy) by Country
Table 67 Other Fluids by Country
Table 68 Clinical Laboratories by Country
Table 69 Pharma & CRO by Country
Table 70 Research by Country

Figure 1 Key Graphic - Comprehensive Profiling Takes Over: Genomic Cancer Panel Market by Panel Size, 2026 vs 2031
Figure 2 The Genomic Progression of Cancer
Figure 3 Germline vs Somatic Mutations
Figure 4 Global Market Pareto Chart
Figure 5 Global Market by Cancer Type - Base vs. Final
Figure 6 Global Market by Cancer Type Base Year
Figure 7 Global Market by Cancer Type End Year
Figure 8 Cancer Type Share by Year
Figure 9 Cancer Type Segments Growth
Figure 10 Global Market by Clinical Use - Base vs. Final
Figure 11 Global Market by Clinical Use Base Year
Figure 12 Global Market by Clinical Use End Year
Figure 13 Clinical Use Share by Year
Figure 14 Clinical Use Segments Growth
Figure 15 Global Market by Panel Size - Base vs. Final
Figure 16 Global Market by Panel Size Base Year
Figure 17 Global Market by Panel Size End Year
Figure 18 Panel Size Share by Year
Figure 19 Panel Size Segments Growth
Figure 20 Global Market by Sample - Base vs. Final
Figure 21 Global Market by Sample Base Year
Figure 22 Global Market by Sample End Year
Figure 23 Sample Share by Year
Figure 24 Sample Segments Growth
Figure 25 Global Market by Customer - Base vs. Final
Figure 26 Global Market by Customer Base Year
Figure 27 Global Market by Customer End Year
Figure 28 Customer Share by Year
Figure 29 Customer Segments Growth
Figure 30 The Changing Age of The World’s Population
Figure 31 Health Care Consumption by Age
Figure 32 Cancer Incidence - Age at Diagnosis
Figure 33 Lung Growth
Figure 34 Breast Growth
Figure 35 Colorectal Growth
Figure 36 Prostate Growth
Figure 37 Gynecological Growth
Figure 38 Blood Cancers Growth
Figure 39 Other Cancers Growth
Figure 40 Therapy Selection & CDx Growth
Figure 41 Hereditary Risk & Germline Growth
Figure 42 Diagnosis & Prognosis Growth
Figure 43 MRD & Monitoring Growth
Figure 44 Screening & Early Detection Growth
Figure 45 Comprehensive Genomic Profiling Growth
Figure 46 Targeted Panels Growth
Figure 47 Hotspot Panels Growth
Figure 48 Tissue Growth
Figure 49 Blood (Liquid Biopsy) Growth
Figure 50 Other Fluids Growth
Figure 51 Clinical Laboratories Growth
Figure 52 Pharma & CRO Growth
Figure 53 Research Growth